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Abstract
Background: Early highly active antiretroviral therapy (HAART), started within the first months
of age, has been proven to be the optimal strategy to prevent immunological and clinical
deterioration in perinatally HIV-infected children. Nevertheless, data about long-term follow-up of
early treated children are lacking.
Methods: We report data from 40 perinatally HIV-infected-children receiving early HAART, with
a median follow-up period of 5.96 years (interquartile range [IQR]:4.21–7.62). Children were
enrolled at birth in the Italian Register for HIV Infection in Children. Comparison with 91 infected
children born in the same period, followed-up from birth, and receiving deferred treatment was
also provided.
Results: Nineteen children (47.5%) were still receiving their first HAART regimen at last follow-
up. In the remaining children the first regimen was discontinued, after a median period of 3.77 years
(IQR: 1.71–5.71) because of viral failure (8 cases), liver toxicity (1 case), structured therapy
interruption (3 cases), or simplification/switch to a PI-sparing regimen (9 cases). Thirty-nine (97.5%)
children showed CD4+ T-lymphocyte values>25%, and undetectable viral load was reached in 31
(77.5%) children at last visit. Early treated children displayed significantly lower viral load than not-
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BMC Infectious Diseases 2009, 9:140 http://www.biomedcentral.com/1471-2334/9/140early treated children, until 6 years of age, and higher median CD4+ T-lymphocyte percentages until
4 years of age. Twenty-seven (29.7%) not-early treated vs. 0/40 early treated children were in
clinical category C at last follow-up (P < 0.0001).
Conclusion: Our findings suggest that clinical, virologic and immunological advantages from early-
HAART are long-lasting. Recommendations indicating the long-term management of early treated
children are needed.
Background
The issue of when to start highly active antiretroviral ther-
apy (HAART) in perinatally HIV-infected children is topi-
cal [1]. Results of a clinical trial investigating the impact of
early HAART on African children have been recently
reported [2]. Among more than 350 children, early
HAART resulted in a 76% reduction in mortality, at 10
month follow-up, confirming that this strategy might be
the preferred choice with respect to deferred therapy. Nev-
ertheless, data regarding the long-term follow-up of early
treated children are lacking. Issue regarding possible side
effects of HAART and lack of compliance have been arisen
[1]. We previously demonstrated benefits from early
HAART in perinatally infected children, on the basis of an
observational study on a large cohort of Italian children
prospectively followed-up from birth [3]. Hereby we
update our previous findings extending the follow-up to
five years.
Methods
Study objective
To compare clinical, immunological and virologic data of
HIV-1 infected children receiving early or deferred
HAART, over a median 5-year follow-up, through an
observational non randomized study.
Data collection
The Italian Register for HIV Infection in Children is a net-
work of 106 pediatric clinics distributed throughout Italy
that is highly representative of the Italian population of
perinatally HIV-infected children; details are described
elsewhere [4,5]. Approval for the study was granted from
the University of Florence and the ethics committees of
the participating institutions, and written informed con-
sent was obtained from children's parents or legal guardi-
ans.
Infection was defined by the persistence of HIV-1 antibod-
ies after 18 months of life or by the detection, on at least
2 occasions, of virus markers (proviral DNA, or viral
RNA). Viral loads were evaluated quantitatively by Ampli-
cor HIV Monitor test and results were expressed as Log10
HIV-1 RNA copies/mL. CD4+ T-lymphocyte counts were
measured using the standardized fluorescent-activated
cell sorting technique. Based on the USA guidelines for the
use of antiretroviral agents in children [6], CD4+ T-lym-
phocyte percentages, rather than their absolute counts,
were taken into account as these percentages more accu-
rately reflect their immune status. HIV-1-related clinical
events were evaluated according to the CDC definition
[7].
Treatment
The specific therapy offered was left to the discretion of
single participating centres. Treatments were considered if
they were given continuously for at least 1 month.
Patients
Patients in the early treatment (n = 40) group were chil-
dren with perinatal HIV-1 infection enrolled in the Regis-
ter at birth, born between January 1996 and January 2007,
satisfying the following conditions: a) treated with
HAART (≥3 antiretroviral drugs) ≤ six months of age; b) in
clinical category CDC N, A, or B before starting HAART; c)
in immunological category CDC 1 or 2 before starting
HAART. Children should remained free of clinical cate-
gory C and/or immunological category 3 diagnoses for 1
month after initiating therapy. Additionally, data from
these children were compared with those from not-early
treated children born in the same period, followed-up
from birth (n = 91). Children who were in CDC category
C before 6 months of age have been excluded from the
analyses.
Statistical analysis
Age, CD4+T-lymphocyte percentages, and viral loads were
expressed as median and interquartile range (IQR). When
the HIV-1 RNA levels were below the lower quantification
limit of the assay, a value was assigned equal to the lower
quantification limit when analyzed as a quantitative vari-
able.
Children receiving early or deferred HAART were com-
pared by viral load, and CD4+ T-lymphocyte percentages
using the Mann-Whitney test. Kaplan-Meier analysis with
Log rank test was performed to analyse differences in sur-
vival and survival free from CDC category C clinical
events. The statistical analyses were performed using the
SPSS software package (SPSS 11.5; Chicago, IL). P < 0.05
was considered statistically significant.Page 2 of 6
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Early treated children were followed-up for 5.96 years
(median; interquartile range [IQR]:4.34–7.48). Median
age at starting HAART was 3.48 months (IQR:2.61–4.14).
Nineteen (47.5%) children were still on their first HAART
regimen at last follow-up. In the remaining children the
first regimen was discontinued because of viral failure (8
cases), liver toxicity (1 case), structured therapy interrup-
tion (3 cases), or simplification/switch to a protease
inhibitor-sparing regimen (9 cases). Thirty-nine (97.5%)
children had CD4+ T-lymphocyte values >25%, at last
check. Undetectable viral load persisted in 31 (77.5%)
children at last visit (Table 1).
Data from early treated children were compared with data
from 91 children not receiving early therapy born in the
same period and followed-up from birth (median follow-
up: 6.9 years [IQR:2.8–9.76]; p = 0.218 vs. early treated
children). Median age at first HAART regimen was of 2.21
years (IQR:1.37-4-76). Eighteen children (19.78%) were
Table 1: Characteristics of 40 perinatal HIV-infected children receiving HAART before 6 months of age.
CDC category Age at first 
HAART (years)
First HAART 
Regimen
Age at first regimen 
discontinuation 
(years)
Reason for 
discontinuation
Age at last follow-
up (years)
CD4+ T cells at 
last follow up (%)
Viral load at last 
follow-up
(Log10 copies/mL)
B1 0.21 DDI+D4T+LPV/r 6.40 Simplification 9.83 42 <1.69
A1 0.18 3TC+D4T+ LPV/r 6.65 Simplification 8.87 28 1.85
B1 0.26 AZT+3TC+NFV Ongoing 8.67 38 <1.69
B2 0.48 AZT+3TC+NFV Ongoing 8.66 37 3.00
A1 0.27 3TC+D4T+NFV 5.00 Simplification 8.75 45 <1.69
A2 0.08 3TC+D4T+NFV Ongoing 8.81 35 <1.69
B1 0.30 AZT+3TC+NFV 4.47 Simplification 8.03 35 <1.69
A1 0.33 ABC+3TC+NFV 7.17 Virologic failure 7.70 28 2.63
A2 0.44 AZT+3TC+NFV Ongoing 8.32 33 <1.69
N1 0.34 AZT+3TC+NVP 3.89 Therapy 
interruption
5.43 38 3.73
A2 0.34 3TC+D4T+NFV Ongoing 6.94 37 <1.69
A1 0.33 AZT+3TC+NFV 1.50 Therapy 
interruption
7.41 31 5.10
A1 0.39 DDI+D4T+NFV 5.71 Simplification 7.28 32 4.00
N1 0.21 DDI+D4T+NFV Ongoing 7.11 30 <1.69
A1 0.34 AZT+3TC+NFV 4.58 Simplification 7.78 44 <1.69
N2 0.13 3TC+D4T+NVP Ongoing 6.40 44 <1.69
A2 0.28 AZT+3TC+NFV Ongoing 6.08 25 <1.69
A1 0.30 3TC+D4T+NFV 6.21 Simplification 6.28 43 <1.69
A2 0.18 DDI+D4T+NFV 3.50 Virologic failure 6.03 39 <1.69
B1 0.36 3TC+D4T+NFV Ongoing 6.24 38 <1.69
A2 0.19 DDI+D4T+NFV 1.64 Therapy 
interruption
6.56 20 <1.69
N1 0.25 AZT+3TC+NVP Ongoing 5.19 42 <1.69
N1 0.42 3TC+D4T+NFV 1.71 Virologic failure 4.39 39 <1.69
A1 0.32 3TC+D4T+NFV 4.30 Simplification 5.04 37 <1.69
N1 0.27 AZT+3TC+NFV 3.21 Simplification 5.15 43 <1.69
N1 0.22 3TC+D4T+NFV Ongoing 4.66 32 <1.69
A1 0.48 AZT+3TC+NVP Ongoing 5.56 34 <1.69
A1 0.45 AZT+3TC+NFV 2.34 Virologic failure 5.88 39 <1.69
B2 0.15 ABC+D4T+NVP Ongoing 4.18 32 <1.69
B1 0.45 3TC+D4T+NFV 2.78 Virologic failure 5.06 28 2.34
B2 0.22 3TC+D4T+ LPV/r 3.77 Virologic failure 5.10 38 <1.69
A2 0.14 AZT+3TC+NVP Ongoing 2.02 51 <1.69
B1 0.43 AZT+3TC+NVP Ongoing 3.89 36 <1.69
N1 0.31 3TC+D4T+NFV Ongoing 2.27 35 2.50
B1 0.24 3TC+D4T+NFV 1.69 Virologic failure 3.83 32 <1.69
N1 0.31 AZT+3TC+NFV Ongoing 0.59 33 2.96
N2 0.25 AZT+3TC+NFV 2.92 Virologic failure 3.41 33 <1.69
N1 0.17 AZT+3TC+NFV Ongoing 2.18 35 <1.69
B1 0.36 ABC+3TC+LPV/r 0.45 Liver toxicity 2.10 42 <1.69
A1 0.23 3TC+D4T+NFV Ongoing 0.88 35 <1.69
Note: ZDV, zidovudine; 3TC, lamivudine; D4T, stavudine; DDI, didanosine; NELF, nelfinavir; LPV/r, lopinavir/ritonavir; NEV, nevirapine; ABC: 
abacavir.Page 3 of 6
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in B, and 27 (29.7%) in C categories, at last observation.
Early treated children displayed significantly lower viral
load than not-early treated children until 6 years of age
(Table 2). Higher median CD4+ T-lymphocyte percentage
was evident until 4 years of age but not at higher age
classes (Table 3). A last follow-up visit 50/91 (54.9%) not-
early treated vs. 31/40 (77.5%) early treated children
reached undetectable viral load (P = 0.001).
Among children receiving early therapy only one child
developed a CDC clinical category A event (lymphaden-
opathy larger than 0.5 cm at more than two sites, at age 19
months) and no child died. Conversely, 48 (51.74%) chil-
dren receiving deferred HAART showed a decline in the
CDC category (9 patients falling to category A, 20 to cate-
gory B, and 18 to category C) and one of these children
died (at age 8.1 years, subsequently to severe sepsis com-
plications.) (P = 0.544, by Kaplan-Meier analysis with
Log-rank test for survival). Twenty-seven (29.67%) not-
early treated vs. 0/40 early treated children were in CDC
clinical category C at last follow-up (P < 0.0001, by Kap-
lan-Meier analysis with Log-rank test) (Figure 1). Time to
failure of the first HAART in children receiving deferred
therapy was 34.2 months (median; IQR:28.0–45.2) in
children receiving early HAART and 29.5 months
(median; IQR:6.8–61.3) in children receiving deferred
HAART.
Discussion
Our study on 40 children with perinatal infection, receiv-
ing early HAART and followed up for a median of 5.96
years, demonstrated that clinical, immunological and
virologic benefits persist over time, indicating that advan-
tages from this kind of strategy are long-lasting. The fact
that the difference in CD4+ T-lymphocyte percentage was
no more statistically significant in children older that 4
Table 3: Differences in CD4+ T-lymphocyte percentages among 40 early treated children and 91 children receiving deferred treatment, 
by age
Age (years)
<1 1 2 3 4 5 6 7 8 9
Median CD4+ 
T-lymphocyte 
percentage 
(IQR)
Early 
treated 
children
36 
(28–50)
38 
(35–43)
38 
(35–42)
36 
(28–40)
35 
(32–41)
35 
(31–42)
36 
(28–39)
38 
(31–39)
37 
(32–38)
35 
(28–42)
Not-early 
treated 
children
34 
(26–45)
31
(23–43)
32 
(24–39)
33 
(27–40)
30 
(22–37)
32 
(25–38)
33 
(35–37)
32 
(26–37)
32 
(27–37)
33 
(24–37)
P* 0.126 0.003 0.001 0.021 0.015 0.107 0.116 0.090 0.126 0.647
Note: IQR: interquartile range; *by Mann-Whitney test.
Table 2: Differences in viral loads among 40 early treated children and 91 children receiving deferred treatment, by age
Age (years)
<1 1 2 3 4 5 6 7 8 9
Median Viral 
load (Log 
RNA copies/
mL) (IQR)
Early 
treated 
children
5.6 
(3.3–5.7)
2.6 
(1.7–3.8)
1.7 
(1.7–3.0)
1.7 
(1.7–2.6)
1.7 
(2.6–3.5)
1,7 
(1.7–2.8)
1,6 
(1.7–2.6)
1.7 
(1.9–4.5)
1.7 
(1.7–2.1)
1.7 
(1.7–1.7)
Not-early 
treated 
children
5.2 
(3.9–5.7)
4.4 
(3.6–5.2)
4.0 
(2.6–4.7)
3.6 
(1.8–4.6)
3.6 
(1.7–4.2)
3.0 
(1.7–4.2)
2.7 
(1.7–3.7)
2.4 
(1.7–3.6)
1.8 
(1.7–3.5)
2.1 
(1.6–4.0)
P* 0.854 <0.0001 <0.0001 <0.0001 0.020 0.021 0.024 0.881 0.131 0.450
Note: IQR: interquartile range; *by Mann-Whitney test.Page 4 of 6
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Indeed, a trend toward higher CD4+ T-lymphocyte per-
centage in early-treated children was evident until 9 years
of age and, likely, it could be confirmed in larger studies.
With respect to our previous findings [3], we found a
lower, but still considerable, proportion of early-treated
children with sustained undetectable viral load at last
check (77%). This rate is similar, or higher than those
reported by other authors [8,9]. This finding is encourag-
ing, even though the possibility to switch to another
HAART regimen in the event of virologic failure, not only
the efficacy of the initial therapy, may have influenced our
results.
Also, with respect to our previous study, we investigated
how children receiving early HAART have been managed
over time. This is a crucial point. Indeed, even if updated
guidelines consider now early therapy as a reasonable
option in children [6], it is still unclear if it should be con-
tinued life-long or stopped after one or more years of age.
In our study the strategy chosen by the Italian pediatri-
cians was not-univocal. The majority of early treated chil-
dren was still on their first HAART regimen at the last
follow-up and displayed good immunological, virologic,
and clinical parameters. Some children experienced mul-
tiple HAART regimens in their life, because of virologic
failure or side effects to therapy, but, even in this group of
children, no immunological or clinical deterioration was
evident at last follow-up. Therapy interruption was
attempted in three children. Two of them were out of ther-
apy at last follow-up visit, maintaining good immunolog-
ical and clinical parameters, while HAART reintroduction
was necessary in the third child because of immunological
decay. Switch to a PI-sparing regimen (mainly with
abacavir or efavirenz) was the chosen option for a minor-
ity of children and it was associated with immunological,
virologic and clinical success in most of them. This point
has been addressed in previous studies, suggesting that
this may be a good strategy [10-13].
No difference in viral load or CD4+ T-lymphocyte percent-
age was present between the two groups at age > 1 year.
Also in both groups, children who were in CDC category
C before 6 months of age have been excluded from the
analysis. Thus, the two groups of children should be com-
parable. Nevertheless, our observational study has some
limitations. Potentially, unmeasured confounders may
have caused the observed differences. Detailed informa-
tion regarding compliance to therapy and viral resistance
mutations was not available. Early treated children could
have motivated families, resulting in better adherence and
better outcomes. Data regarding detailed reasons that led
to the treatment interruption or PI substitution were not
available. Physicians who took care for these children may
have simplified the therapy in order to reduce possible
long-term metabolic toxicity effects of PIs. Accordingly,
other authors demonstrated that a PI-sparing regimen
may be a good strategy in children [10-13].
Conclusion
In conclusion, our previous findings are substantially
strengthened by these additional data on a long term fol-
low-up, confirming benefits of early HAART. Our observa-
tional study may not solve the issue regarding the optimal
strategy for long term managing of early treated children.
Even if this is only a speculation, it is possible that use of
a PI-sparing regimen might represent a good option. This
is in agreement with results from a Belgian study, includ-
ing about twenty children receiving early therapy with a
protease inhibitor-sparing HAART [10]. Guidelines indi-
cating the subsequent management of early treated chil-
dren are needed.
Abbreviations
CDC: Centers for Disease Control and Prevention; IQR:
interquartile range; HAART: active antiretroviral therapy;
PI: protease inhibitor.
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